WASHINGTON — Health secretary Robert F. Kennedy Jr. and many top deputies are scheduled to speak alongside industry executives and health activists at a daylong MAHA event on Wednesday that has not been publicly disclosed by administration officials or event organizers.
<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-5362842976017675"
crossorigin="anonymous"></script>
The event, called the MAHA Summit, will take place at the gilded Waldorf Astoria hotel in Washington. The agenda, obtained by STAT, includes the most powerful health officials across the federal government: CMS Administrator Mehmet Oz, FDA Commissioner Marty Makary, NIH Director Jay Bhattacharya, acting CDC Director and HHS Deputy Secretary Jim O’Neill, Medicare Director Chris Klomp, White House artificial intelligence czar David Sacks — and even Vice President JD Vance.
They plan to talk to industry and MAHA leaders about a wide range of high-priority issues, from the future of the FDA and NIH to artificial intelligence in health care, biotech development, GLP-1s, and food as medicine. Those in attendance will also be able to take advantage of “exclusive networking” with the powerful leaders, according to a copy of the invite viewed by STAT.
A highly exclusive gathering titled the “Hush Hush” MAHA Summit is set to bring together some of the most influential voices in politics, business, and biotechnology. Among the notable attendees are Robert F. Kennedy Jr., Senator JD Vance, and several prominent biotech industry leaders.
The summit, which will be held behind closed doors, is designed as a high-level forum for private discussions on the future of biotechnology, innovation policy, and public health. Sources familiar with the event say it aims to foster open dialogue between policymakers and industry pioneers on how emerging technologies can reshape medicine and the economy.
While details about the agenda remain limited, topics are expected to include biotech regulation, AI-driven health solutions, and global biosecurity challenges. The event’s discreet nature has drawn curiosity from observers, given the growing intersection of biotech advances with political and ethical debates.
Organizers have emphasized that the summit’s invitation-only approach encourages candid exchanges among participants without the constraints of public scrutiny. “The goal is to explore bold ideas and build trust across sectors,” one insider reportedly said.
With high-profile attendees and the rising influence of biotechnology in public policy, the MAHA Summit is shaping up to be one of the most talked-about private events of the year — even if much of what happens inside stays, as the name suggests, hush hush.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account?
View All Plans
To read the rest of this story subscribe to STAT+.
